BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Xanodyne Pharmacal, Inc. And Integrity Pharmaceutical Corporation To Merge; Combination Creates Strong, Fully Integrated Specialty Pharma Company


10/19/2005 5:09:23 PM

Combination Creates Strong, Fully Integrated Specialty Pharma Company

FLORENCE, Ky.--(BUSINESS WIRE)--Dec. 4, 2003--Xanodyne(TM) Pharmacal, Inc. announced today it will join forces with Indianapolis-based Integrity® Pharmaceutical Corporation, creating a product development and marketing company with significant growth potential. The new company will focus on the specialty medicine fields of pain management, bleeding disorders, urology and women's health. The new entity, with some 150 employees, will operate as Xanodyne Pharmaceuticals, Inc. and be headquartered in Florence, KY, in the greater Cincinnati, Ohio area.

Xanodyne Pharmacal and Integrity Pharmaceutical were both founded and launched by the Union Springs, LLC, private-equity group, which focuses exclusively on investments in the life-sciences sector. Roger D. Griggs, Chairman of Union Springs, will continue in his role as Chairman of the Board, providing strategic counsel to the new integrated company.

"Each organization brings its unique strengths to the new enterprise," said Stefan Antonsson, President, Xanodyne Pharmaceuticals. "Xanodyne offers an experienced, targeted specialty sales force, a strong product development capability and an extensive pipeline of products. Integrity contributes a proven sales force, manufacturing capability and a respected presence in urology and women's health. Both companies have strong, complementary management teams and commercial capabilities. Both companies are generating increased sales from a diversified portfolio of marketed products which, when combined, create the critical mass to substantially accelerate our future growth," he added.

In addition to higher revenues, Xanodyne Pharmaceuticals benefits from greater sales and marketing muscle enabling the new company to launch new products more effectively. The combined company will have an extensive drug development pipeline with plans to launch a number of new products in the short and mid term. The company also plans to initiate several large clinical studies to support innovative products at earlier stages of development.

"Integrity sought to build a competitive advantage through its pharmaceutical products in obstetrics/gynecology and urology," notes Terri Pascarelli, president of Integrity, who is charged with leading the integration of the two companies. "The combination of Xanodyne and Integrity forms a powerful competitive force in the therapeutic areas of pain management, bleeding disorders, urologic concerns and women's health. "

"This merger best positions our people, products and pipeline for success," said Mr. Antonsson. "It will enable us to move compounds seamlessly from development to production and, with enhanced marketing and sales capacity, quickly to the physician community. It improves corporate agility and the ability to more rapidly convert product innovation into patient solutions," he added.

Resulting from the merger, new executive appointments include:

Stefan Antonsson, president of Xanodyne Pharmacal, has been appointed president of Xanodyne Pharmaceuticals. He continues to report to Roger Griggs, chairman of the board. The following individuals report to Stefan Antonsson:

Terri Pascarelli, president of Integrity Pharmaceuticals, Inc., is charged with leading the integration of the two companies.

Tom Jennings, president, Union Springs, LLC, will serve as corporate secretary for Xanodyne Pharmaceuticals. Jim Young, Ph.D. has been named vice president, product development and professional services for the new company.

Bob Estey has been named vice president, finance, for Xanodyne Pharmaceuticals. Blake Paterson, MD has been named executive vice president, urology business unit, for the new company. Barry Brandstetter, has been named vice president, marketing, Xanodyne Pharmaceuticals, Inc. Jon Brewer and John Egger have been named vice presidents of sales for the organization. Xanodyne Pharmaceuticals, Inc. is a privately owned, fully integrated, branded specialty pharmaceutical company focusing on innovative products in the therapeutic areas of pain management, bleeding disorders, urology and women's health. The company, located in the greater Cincinnati area, has a nationwide sales force and currently markets numerous pharmaceutical products including Amicar®, DexAlone®, Lucidex®, Duet(TM) by StuartNatal®, Duet(TM) DHA by StuartNatal®, Stuart Prenatal®, and Urimax®. Xanodyne also has a number of novel new products under development.

Contact:

Makovsky & Company for Xanodyne Pharmaceuticals Kristie Kuhl, 212-508-9642 kkuhl@makovsky.com

Source: Xanodyne Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES